BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Stock Plummets 18% Amid Obesity Drug Pipeline Concerns
Eli Lilly Stock Plummets 18% Amid Obesity Drug Pipeline Concerns
15
2
BTCCSquare news:
Eli Lilly's shares tumbled 18% this week, marking a stark reversal for the pharmaceutical giant. The $500 billion behemoth faces headwinds despite a 300% five-year rally fueled by its blockbuster weight-loss drugs. Second-quarter revenues surged 38% to $15.5 billion, with Mounjaro and Zepbound delivering 68% and 172% growth respectively. Yet investors balked at two critical concerns.
Potential US pharmaceutical tariffs threaten to disrupt cost structures, while disappointing trial data for experimental drug orfoglipron revealed alarming patient dropout rates. The market's reaction underscores how even industry leaders face turbulence when growth narratives encounter regulatory and clinical hurdles.
By:
